Pathogenic variants of ADAM22 affecting either its biosynthesis and/or its interactions with either LGI1 and/or PSD-95 have been recently identified in individuals with developmental and epileptic encephalopathy. This evidence concerns the gene ADAM22 and developmental and epileptic encephalopathy.